The presence of mutations within DDR1 kinase domain in multiple cancers, such as non‐small cell lung cancer (Ford et al., 2007) and acute myeloid leukemia (Tomasson et al., 2008), which may result in the resistance to small molecular inhibitors, has been reported. The gene discussed is DDR1; the disease is acute myeloid leukemia.